324 related articles for article (PubMed ID: 29753129)
1. Applications of RNA Indexes for Precision Oncology in Breast Cancer.
Ma L; Liang Z; Zhou H; Qu L
Genomics Proteomics Bioinformatics; 2018 Apr; 16(2):108-119. PubMed ID: 29753129
[TBL] [Abstract][Full Text] [Related]
2. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
4. Identification of Potential Long Non-Coding RNA Candidates that Contribute to Triple-Negative Breast Cancer in Humans through Computational Approach.
Rahman MM; Hossain MT; Reza MS; Peng Y; Feng S; Wei Y
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830241
[TBL] [Abstract][Full Text] [Related]
5. Genomic Alterations Affecting Competitive Endogenous RNAs (ceRNAs) and Regulatory Networks (ceRNETs) with Clinical Implications in Triple-Negative Breast Cancer (TNBC).
Qattan A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473871
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
7. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.
Asleh K; Riaz N; Nielsen TO
J Exp Clin Cancer Res; 2022 Sep; 41(1):265. PubMed ID: 36050786
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.
Tang Q; Ouyang H; He D; Yu C; Tang G
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2800-2809. PubMed ID: 31284781
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
14. Circular RNA-associated ceRNA network involved in HIF-1 signalling in triple-negative breast cancer: circ_0047303 as a potential key regulator.
Darbeheshti F; Mahdiannasser M; Noroozi Z; Firoozi Z; Mansoori B; Daraei A; Bastami M; Nariman-Saleh-Fam Z; Valipour E; Mansoori Y
J Cell Mol Med; 2021 Dec; 25(24):11322-11332. PubMed ID: 34791795
[TBL] [Abstract][Full Text] [Related]
15. The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data.
Raju R; Paul AM; Asokachandran V; George B; Radhamony L; Vinaykumar M; Girijadevi R; Pillai MR
Breast Cancer Res; 2014 Dec; 16(6):490. PubMed ID: 25472854
[TBL] [Abstract][Full Text] [Related]
16. Update on Precision Medicine in Breast Cancer.
Sachdev JC; Sandoval AC; Jahanzeb M
Cancer Treat Res; 2019; 178():45-80. PubMed ID: 31209841
[TBL] [Abstract][Full Text] [Related]
17. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Wang X; Guda C
Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of the potential roles of miRNA‑mRNA networks in triple negative breast cancer.
Zhu H; Dai M; Chen X; Chen X; Qin S; Dai S
Mol Med Rep; 2017 Aug; 16(2):1139-1146. PubMed ID: 28627677
[TBL] [Abstract][Full Text] [Related]
19. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.
Darbeheshti F; Mansoori Y; Azizi-Tabesh G; Zolfaghari F; Kadkhoda S; Rasti A; Rezaei N; Shakoori A
Biochem Genet; 2023 Aug; 61(4):1487-1508. PubMed ID: 36645554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
